Evidence map›Paper›PMID 38883124›Full record

ArticleCureus2024

Secretory Carcinoma of the Breast: A Rare Entity With Favorable Prognosis.

Souad Margoum, Soufiane Berhili, Meriem Bouabid, Mohamed Moukhlissi, Mezouar Loubna

Abstract readCase Reports
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Souad MargoumRadiation Oncology, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, MAR.
Soufiane BerhiliRadiation Oncology, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, MAR.
Meriem BouabidRadiation Oncology, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, MAR.
Mohamed MoukhlissiRadiation Oncology, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, MAR.
Mezouar LoubnaRadiation Oncology, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, MAR.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Secretory breast carcinoma (SBC) is an extremely rare entity of breast cancer, which can affect all age groups. The diagnosis is based on the characteristic microscopic appearance, and despite the triple negativity or low hormone receptor positivity, SBC is generally characterized by a favorable prognosis. Due to the rarity of the disease, no clear consensus on optimal treatment is available. Nevertheless, conservative surgery or mastectomy is the main therapeutic option. The efficacy of chemotherapy, radiotherapy, and hormone therapy in this pathology has not been rigorously explored. We report the case of a 65-year-old woman with SBC treated with surgery and adjuvant radiotherapy, with a review of the literature.

Indexed as

breastbreast cancercase reportprognosissecretory carcinoma of the breasttreatment

Identifiers

PMID38883124
PMCPMC11179585

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.